Office-based labs

Extensive vascular portfolio

Choose an office-based lab (OBL) partner that covers the procedures you perform today, and the ones you're planning for in the future.

You’ll gain access to one of the largest portfolios of products in med tech when you partner with us. We offer a comprehensive suite of products and therapies to treat varying degrees of vascular disease to help your patients get back to enjoying what they love.

  1. Peripheral embolization
  2. Superficial venous
  3. Deep venous
  4. Carotid
  5. Arteriovenous access
  6. Iliac, superficial femoral (SFA), and popliteal arteries
  7. Below the knee (BTK)
Illustration of the human anatomy showing blood flow in the peripheral vascular system with numbered callouts

About 80% of peripheral vascular interventions today have been reported to be catheter-based and can be performed in an OBL.1 Our extensive selection of vascular products includes:

Product spotlight

HawkOne directional atherectomy system on transparent background

HawkOne™ Directional Atherectomy 

Treat above and below the knee with the HawkOne directional atherectomy system to restore blood flow by removing plaque in patients with peripheral arterial disease.

VenaSeal closure system on transparent background

VenaSeal™ Closure System

Reach new lengths and treat more diseased vein with VenaSeal closure system. Deliver immediate and lasting vein closure with our proprietary medical adhesive2-6 and provide patients with a rapid, same-day recovery.

Ellipsys vascular access system on transparent background

Ellipsys™ Vascular Access System

The Ellipsys system transforms the standard surgical arteriovenous (AV) fistula creation into minimally invasive procedure that requires no implant or suture, and allows patients to leave with just a single puncture.7

References

1

Aurshina A, Ostrozhynskyy Y, Alsheekh A, et al. Safety of vascular interventions performed in an office-based laboratory in patients with low/moderate procedural risk. J Vasc Surg. April 2021;73(4):1298-1303.

2

Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. April 2015;61(4):985-994.

3

Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on Cyanoacrylate Embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. March 2021;9(2):329-334.

4

Gibson K, Ferris B. Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: Initial outcomes of a post-market evaluation of the VenaSeal System (the WAVES Study). Vascular. April 2017;25(2):149-156.

5

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. September 2017;5(5):658-666.

6

Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. November 2020;8(6):978-989.

7

Hull JE, Jennings WC, Cooper RI, Waheed U, Schaefer ME, Narayan R. The Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula Creation for Hemodialysis Access. J Vasc Interv Radiol. February 2018;29(2):149-158.e5.